Vibegron (brand name Vibegron) is a newer beta-3 adrenergic agonist approved for adult overactive bladder with urge urinary incontinence, urgency, and urinary frequency. Like mirabegron, it relaxes the bladder during storage — but with a pharmacokinetic profile that offers some practical advantages for California OAB patients.
How Vibegron Differs from Mirabegron
Both vibegron and mirabegron target beta-3 receptors in the bladder wall. Key differences include drug metabolism — vibegron has minimal drug-drug interactions via the CYP3A4 pathway, which is relevant for San Diego patients taking multiple medications (a common situation). This makes vibegron a potentially cleaner pharmacological choice for California women on complex medication regimens.
What Vibegron Is Approved For
Vibegron is FDA-approved for the treatment of adult OAB with urgency, urge urinary incontinence, and urinary frequency. It is taken once daily.
Side Effects
Vibegron's side effect profile is generally favorable. Headache, urinary tract infection, and nasopharyngitis are the most commonly reported events in clinical trials. Like mirabegron, vibegron does not carry the anticholinergic cognitive concerns associated with antimuscarinic OAB medications.
Blood Pressure Considerations
Vibegron's effect on blood pressure is modest. Some elevation may occur, and San Diego patients with significant hypertension should have blood pressure monitored when initiating vibegron therapy.
When Vibegron Is Not Enough
If vibegron has not provided adequate OAB symptom relief, or if multiple medication trials have been unsuccessful, sacral neuromodulation and tibial nerve stimulation are available at California Bladder's San Diego locations. These are covered by Medicare, Aetna, Blue Cross, Cigna, and UnitedHealthcare when criteria are met. Call (858) 571-3630 to schedule.
This article is for informational purposes only and does not constitute medical advice. Coverage information is general; individual plan requirements vary. A clinical evaluation is required.